Staging and Prognosis: Understanding the Path Forward

Once your treatment is planned, staging and prognosis are the tools doctors use to answer two critical questions: “How advanced is the cancer?” and “What is the likely outcome?” For bone sarcoma, these answers are based on the tumor’s size, its “grade” (how aggressive the cells look), and—most importantly—whether it has spread to other parts of the body.

The Two Staging Systems

Because bone sarcomas are unique, doctors often use two different systems to describe them.

1. The Enneking (MSTS) System

This system is widely used by orthopedic surgeons because it focuses on how difficult the tumor will be to remove surgically ^[1]. It uses three factors:

• Grade (G): Is it Low Grade (G1) or High Grade (G2)?
• Site (T): Is the tumor intracompartmental (T1, contained within the bone/muscle) or extracompartmental (T2, has broken out into surrounding tissues)? ^[2]
• Metastasis (M): Has it spread to other organs (M1)?

2. The AJCC (TNM) System

The American Joint Committee on Cancer (AJCC) system is more detailed and is used by medical oncologists to plan chemotherapy. It looks at:

• Tumor Size: Is the tumor smaller or larger than 8 cm?
• Nodes: Has it reached nearby lymph nodes?
• Metastasis: Has it reached the lungs or other bones?

The Most Significant Factor: Spread

The presence of distant metastasis (cancer that has traveled away from the original site) is the single most important factor in determining prognosis ^[3].

• Lungs: Bone sarcomas most commonly spread to the lungs. If the cancer is caught while it is still localized (only in the bone), survival rates are much higher ^[3].
• Skip Lesions: Doctors also look for “skip lesions”—smaller tumors in the same bone but separate from the main mass. Their presence typically indicates a more aggressive disease.

The Huvos Grade: Measuring Success (Necrosis Rate)

For patients with Osteosarcoma and Ewing Sarcoma who receive neoadjuvant chemotherapy (chemo before surgery), the most critical piece of prognostic information comes after the tumor is removed. A pathologist examines the tumor under a microscope to calculate the necrosis rate—the percentage of the tumor that was killed by the chemotherapy ^[4].

This is measured using the Huvos Grading System:

• Grade I & II (Poor Response): Less than 90% of the tumor cells are dead ^[4][5].
• Grade III & IV (Good Response): 90% to 100% of the tumor cells are dead ^[4][5].

A “Good Responder” (≥90% necrosis) generally has a significantly better long-term outlook ^[6][7]. If a patient is a “Poor Responder,” the medical team may discuss whether to adjust the chemotherapy drugs used after surgery to try a different approach ^[8].

Other Prognostic Clues

Beyond staging and necrosis, other factors help doctors understand the risk:

• Location: Tumors in the extremities (arms/legs) often have a better prognosis than those in the axial skeleton (pelvis or spine), simply because they are easier to remove with clear margins ^[9].

• Blood Markers: High levels of certain enzymes in the blood, such as ALP (Alkaline Phosphatase) or LDH (Lactate Dehydrogenase), can sometimes indicate a more active or aggressive tumor ^[10].

• Tumor Size: Generally, tumors larger than 8 cm are considered higher risk than smaller ones.

• Next: Learn about Survivorship and Beyond